Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03028870 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
A Phase 2 study, sponsored by Purdue Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 291
- Enrollment target
NCT03028870: Completed Phase 2 study, sponsored by Purdue Pharma.
NCT03028870 is a Phase 2 study that has completed, run by Purdue Pharma. The registered enrollment target is 291 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (119% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03028870, a Phase 2 study, has completed, sponsored by Purdue Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 291 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
Primary Outcome
At week 4, subjects were asked to rate their pain on an 11-point numerical scale where 0 = no pain, 10 = pain as bad as you can imagine.
Interventions
- DRUG Placebo
- DRUG Naproxen
- DRUG V120083
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 291 participants |
| Start Date | 2017-03-14 |
| Est. Completion | 2017-11-21 |
| Phase | Phase 2 |
What the finished NCT03028870 record still lists
NCT03028870 is an interventional study that assigns participants to a tested intervention. The registered 291 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (119% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03028870 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03028870 about?
NCT03028870 is a clinical study titled "A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee". The purpose of this study is to evaluate the analgesic efficacy of V120083 twice daily compared to placebo in subjects with moderate to severe chronic pain due to OA of the knee.
What is the current status of trial NCT03028870?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 291 participants. The study started on 2017-03-14. Estimated completion is 2017-11-21.
What interventions are being tested in trial NCT03028870?
The interventions under investigation include: Placebo (DRUG), Naproxen (DRUG), V120083 (DRUG).
Who is sponsoring clinical trial NCT03028870?
This trial is sponsored by Purdue Pharma, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03028870's enrollment target sits among peer trials
291 191st of 2000 higher than 1,810 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02074839 · 291 participants · Phase 1
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
- NCT03769766 · 291 participants · Phase 3
Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
- NCT06563479 · 291 participants · Phase 3
A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer
- NCT04429542 · 292 participants · Phase 1
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI